MA40415A - Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques - Google Patents

Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques

Info

Publication number
MA40415A
MA40415A MA040415A MA40415A MA40415A MA 40415 A MA40415 A MA 40415A MA 040415 A MA040415 A MA 040415A MA 40415 A MA40415 A MA 40415A MA 40415 A MA40415 A MA 40415A
Authority
MA
Morocco
Prior art keywords
cell
agents
conjugates
cytotoxic
binding
Prior art date
Application number
MA040415A
Other languages
English (en)
French (fr)
Inventor
Ravi V J Chari
Nathan Elliott Fishkin
Luke B Harris
Michael Louis Miller
Lingyun Rui
Manami Shizuka
Daniel Tavares
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of MA40415A publication Critical patent/MA40415A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA040415A 2014-09-03 2015-09-02 Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques MA40415A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462045264P 2014-09-03 2014-09-03
US201462086986P 2014-12-03 2014-12-03
US201562149379P 2015-04-17 2015-04-17
US201562186235P 2015-06-29 2015-06-29

Publications (1)

Publication Number Publication Date
MA40415A true MA40415A (fr) 2016-03-10

Family

ID=54147280

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040415A MA40415A (fr) 2014-09-03 2015-09-02 Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques

Country Status (13)

Country Link
US (3) US10988531B2 (OSRAM)
EP (1) EP3188733B1 (OSRAM)
JP (1) JP2017529837A (OSRAM)
KR (3) KR102638901B1 (OSRAM)
CN (1) CN107580604A (OSRAM)
AU (1) AU2015312075A1 (OSRAM)
CA (1) CA2957964A1 (OSRAM)
IL (1) IL250711A0 (OSRAM)
MA (1) MA40415A (OSRAM)
RU (1) RU2017110068A (OSRAM)
SG (2) SG10201901825YA (OSRAM)
TW (1) TW201609152A (OSRAM)
WO (1) WO2016036794A1 (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109147874A (zh) * 2014-09-02 2019-01-04 伊缪诺金公司 用于配制抗体药物缀合物组合物的方法
ES2815353T3 (es) * 2014-09-03 2021-03-29 Immunogen Inc Derivados de benzodiazepina citotóxicos
KR102638901B1 (ko) 2014-09-03 2024-02-22 이뮤노젠 아이엔씨 세포-결합제 및 세포독성 약물을 포함하는 콘주게이트
IL282614B2 (en) 2015-02-06 2024-02-01 Cell Idx Inc Antigen-conjugated immune reagents
CN114672490A (zh) * 2015-06-29 2022-06-28 伊缪诺金公司 抗cd123抗体以及其缀合物和衍生物
SI3325482T1 (sl) * 2015-07-21 2020-11-30 Immunogen, Inc. Postopki za pripravo citotoksičnih benzodiazepinskih derivatov
TN2018000264A1 (en) * 2016-02-05 2020-01-16 Immunogen Inc Gcc-targeted antibody-drug conjugates
CN108472371B (zh) * 2016-07-05 2022-05-24 江苏恒瑞医药股份有限公司 Egfr抗体-药物偶联物及其在医药上的应用
JP7618383B2 (ja) * 2016-07-22 2025-01-21 ネクター セラピューティクス オキシム含有リンケージを有する第ｖｉｉｉ因子部分のコンジュゲート
SG11201903842YA (en) * 2016-11-02 2019-05-30 Immunogen Inc Combination treatment with antibody-drug conjugates and parp inhibitors
WO2018112334A1 (en) 2016-12-16 2018-06-21 Bluefin Biomedicine, Inc. Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof
TWI783957B (zh) * 2016-12-23 2022-11-21 美商伊繆諾金公司 靶向adam9之免疫共軛物及其使用方法
TWI862991B (zh) * 2017-02-28 2024-11-21 美商伊繆諾金公司 具有自分解肽連接子之類美登素衍生物及其結合物
WO2018183494A1 (en) * 2017-03-31 2018-10-04 Immunogen, Inc. Cd19-targeting antibody-drug conjugates
AU2018305726B2 (en) * 2017-07-26 2022-09-15 The University Of Queensland Disulfide bond containing compounds and uses thereof
CN117003875A (zh) 2017-09-29 2023-11-07 第一三共株式会社 抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用
US20200362054A1 (en) * 2017-11-21 2020-11-19 Brian Granda Trispecific binding molecules against tumor-associated antigents and use thereof
US11274121B2 (en) * 2018-01-12 2022-03-15 Immunogen, Inc. Methods for antibody drug conjugation, purification, and formulation
SG11202007494TA (en) 2018-03-13 2020-09-29 Phanes Therapeutics Inc Anti-folate receptor 1 antibodies and uses thereof
CN112272556B (zh) 2018-04-10 2023-12-19 塞勒科塔生物科学公司 磷脂-flavagline缀合物及将其用于靶向癌症治疗的方法
WO2020016661A2 (en) * 2018-07-09 2020-01-23 Multitude Inc. Antibodies specific to folate receptor alpha
WO2020060944A1 (en) * 2018-09-17 2020-03-26 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
TWI897855B (zh) * 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
WO2020092631A1 (en) * 2018-10-31 2020-05-07 Fred Hutchinson Cancer Research Center Compositions and methods for detecting and treating cancers characterized by expression of mesothelin
US20210032285A1 (en) * 2019-03-11 2021-02-04 Cell Idx, Inc. Methods, compositions, and kits for trapping modified biomolecules
CN120131907A (zh) 2019-03-19 2025-06-13 瓦尔希伯伦私人肿瘤研究基金会 采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法
CN113631194A (zh) * 2019-03-21 2021-11-09 伊缪诺金公司 制备细胞结合剂-药物缀合物的方法
CU20210096A7 (es) 2019-05-21 2022-06-06 Novartis Ag Moléculas de unión a cd19
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
JP7631329B2 (ja) 2019-10-10 2025-02-18 セレクター・バイオサイエンシズ・インコーポレイテッド リン脂質－フラバグリン抱合体及び標的化されたがん治療のためのリン脂質－フラバグリン抱合体の使用方法
CN110922482B (zh) * 2019-12-25 2021-08-31 源道隆（苏州）医学科技有限公司 可结合cd19的多肽及其应用
CN112794911B (zh) * 2021-04-14 2021-08-03 上海偌妥生物科技有限公司 人源化抗叶酸受体1抗体及其应用
CN113908589B (zh) * 2021-10-08 2022-09-27 天津工业大学 一种表面印迹抗体的疏水电荷诱导模式膜层析介质及其制备方法
EP4608429A1 (en) 2022-10-25 2025-09-03 Peptomyc, S.L. Combination therapy for the treatment of cancer
TW202502371A (zh) 2023-06-07 2025-01-16 瓦爾希伯倫私人腫瘤研究基金會 用於治療癌症的與ｂｒａｆ抑制劑的組合療法
EP4473974A1 (en) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer
TW202513088A (zh) 2023-06-07 2025-04-01 瓦爾希伯倫私人腫瘤研究基金會 用於治療癌症的與ｍｅｋ抑制劑的組合療法
CN117659041A (zh) * 2023-12-08 2024-03-08 联宁（苏州）生物制药有限公司 用于抗体偶联药物的氘代蒽环类毒素连接子及其合成方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362852A (en) * 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
FR2801904B1 (fr) 1999-12-07 2002-02-08 Pasteur Institut Produits comprenant un support sur lequel sont fixes des acides nucleiques et leur utilisation comme puce a adn
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
EP1539804B1 (fr) 2002-09-19 2007-01-03 Centre National De La Recherche Scientifique (Cnrs) Synthese et caracterisation de nouveaux systemes de guidage et de vectorisation de molecules d'interet therapeutique vers des cellules cibles.
CN102319437B (zh) 2002-12-26 2017-10-13 山景医药公司 具有增强的生物学效用的干扰素‑β的聚合物缀合物
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
WO2006042848A2 (en) 2004-10-18 2006-04-27 Novo Nordisk A/S Growth hormone conjugates
EP1861417B1 (en) 2005-03-10 2013-05-15 BioNTech AG Dimeric or multimeric microproteins
WO2006115416A2 (en) 2005-04-25 2006-11-02 Ge Healthcare As Liposomes
JP4938263B2 (ja) * 2005-08-19 2012-05-23 独立行政法人農業生物資源研究所 一本鎖抗体によるサイトゾルタンパク質の機能阻害法およびその利用
WO2007048127A2 (en) 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
FR2897616B1 (fr) 2006-02-20 2008-05-30 Univ Grenoble 1 Presentation de motifs de reconnaissance par une matrice multivalente greffee sur un support solide
US7985783B2 (en) * 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
CN106432496B (zh) 2007-07-16 2020-02-07 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
SI2211904T1 (sl) 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
EP2214700A4 (en) 2007-11-02 2012-08-22 Janssen Biotech Inc HALF-SYNTHETIC GLP-1 PEPTIDE FUSION CONSTRUCTS, METHOD AND USES
BRPI0911442A2 (pt) * 2008-04-30 2019-03-12 Immunogen, Inc. conjugados potentes e ligantes hidrofílicos
TWI796132B (zh) * 2010-02-24 2023-03-11 美商免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
US9381058B2 (en) * 2010-11-05 2016-07-05 Ethicon Endo-Surgery, Llc Recharge system for medical devices
WO2012112708A1 (en) * 2011-02-15 2012-08-23 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and methods of preparation
SG11201407106XA (en) 2012-05-01 2014-11-27 Genentech Inc Anti-pmel17 antibodies and immunoconjugates
WO2013174003A1 (en) * 2012-05-24 2013-11-28 Mountgate Group Limited Compositions and methods related to prevention and treatment of rabies infection
KR20150018870A (ko) 2012-06-06 2015-02-24 바이오노르 이뮤노 에이에스 면역원 및 투여 반응제로서 사용하기 위한 바이러스 단백질로부터 유래하는 펩타이드
US9834597B2 (en) 2012-09-21 2017-12-05 The Regents Of The University Of California Modified FC polypeptides, FC conjugates, and methods of use thereof
EP3300108B1 (en) * 2013-03-28 2019-07-24 Toshiba Hokuto Electronics Corporation Light emitting device and method for manufacturing the same
WO2014186301A1 (en) 2013-05-13 2014-11-20 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging
ES2883191T3 (es) * 2013-08-30 2021-12-07 Immunogen Inc Anticuerpos y ensayos para la detección del receptor 1 de folato
JP6609563B2 (ja) 2013-11-26 2019-11-20 ノバルティス アーゲー ケトンで修飾されたポリペプチドをオキシム複合化する方法
KR102638901B1 (ko) 2014-09-03 2024-02-22 이뮤노젠 아이엔씨 세포-결합제 및 세포독성 약물을 포함하는 콘주게이트

Also Published As

Publication number Publication date
RU2017110068A (ru) 2018-10-03
US11732038B2 (en) 2023-08-22
KR102638901B1 (ko) 2024-02-22
JP2017529837A (ja) 2017-10-12
CN107580604A (zh) 2018-01-12
WO2016036794A1 (en) 2016-03-10
SG10201901825YA (en) 2019-03-28
US20210299271A1 (en) 2021-09-30
IL250711A0 (en) 2017-08-31
EP3188733B1 (en) 2019-11-06
EP3188733A1 (en) 2017-07-12
US20240190956A1 (en) 2024-06-13
AU2015312075A1 (en) 2017-03-09
US10988531B2 (en) 2021-04-27
CA2957964A1 (en) 2016-03-10
SG11201701565PA (en) 2017-03-30
TW201609152A (zh) 2016-03-16
US20160095938A1 (en) 2016-04-07
KR102508023B1 (ko) 2023-03-10
KR20230039755A (ko) 2023-03-21
KR20240027148A (ko) 2024-02-29
KR20170054430A (ko) 2017-05-17
RU2017110068A3 (OSRAM) 2019-08-26

Similar Documents

Publication Publication Date Title
MA40415A (fr) Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
MY190504A (en) Pyrrolobenzodiazepine conjugates
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2021010550A (es) Conjugados de anticuerpo-farmaco hidrofilicos.
PH12016501411B1 (en) Bifunctional cytotoxic agents
LT3319993T (lt) Axl specifiniai antikūno-vaistokonjugatai, skirti vėžiui gydyti
EP3566750A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
EA201791359A1 (ru) Конъюгаты, связывающие белок-лекарственное средство, содержащие производные антрациклина
TW201613641A (en) Anti-CD22 antibody-drug conjugates and methods of using thereof
MX2019010950A (es) Composicion de fotosensibilizador que contiene fenalen-1-ona, compuesto de fenalen-1-ona, asi como su uso.
WO2014134457A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
ZA201803476B (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
WO2014134486A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
EA201890186A1 (ru) Применение штаммов микробактерий для получения антибактериальных агентов
MX2016012258A (es) Dosificacion optima de un conjugado del farmaco del anticuerpo-cd19.
PH12017501869A1 (en) (s)-2'-vinyl-abscisic acid derivatives
PH12016502592A1 (en) 3'-substituted-abscisic acid derivatives
MX2017008655A (es) Derivados de jasmonato y composiciones de los mismos.
IN2013DE03665A (OSRAM)
HK1234311A1 (en) Novel anti-rnf43 antibodies and methods of use
UA105615U (uk) Сполука n-пара-бромфеніл-3-(уридин-5'-аміно)-сукцинімід, яка має потенційну фізіологічну властивість